Nanjing Hicin Pharmaceutical Co Ltd Net Asset Quality Index
Nanjing Hicin Pharmaceutical Co Ltd net asset quality index. Nanjing Hicin Pharmaceutical Co Ltd (300584) has a Net Asset Quality Index of 73.9% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.52 Billion minus total liabilities of CN¥395.57 Million yields net assets of CN¥1.12 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 300584 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Nanjing Hicin Pharmaceutical Co Ltd (2012–2025)
Net asset quality index of Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Nanjing Hicin Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the index stands at 73.9%, representing net assets of CN¥1.12 Billion against total assets of CN¥1.52 Billion CNY. See Nanjing Hicin Pharmaceutical Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Nanjing Hicin Pharmaceutical Co Ltd Net Asset Quality Index by Year (2012–2025)
Nanjing Hicin Pharmaceutical Co Ltd net asset quality index by year from 2012 to 2025. The table below presents the year-by-year Net Asset Quality Index for Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Nanjing Hicin Pharmaceutical Co Ltd stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 71.8% | CN¥1.10 Billion | CN¥1.53 Billion | CN¥432.26 Million | ▲ +0.9 pp |
| 2024 | 70.9% | CN¥1.04 Billion | CN¥1.46 Billion | CN¥426.37 Million | ▲ +0.8 pp |
| 2023 | 70.1% | CN¥987.50 Million | CN¥1.41 Billion | CN¥421.37 Million | ▼ -3.4 pp |
| 2022 | 73.5% | CN¥950.57 Million | CN¥1.29 Billion | CN¥343.38 Million | ▲ +0.6 pp |
| 2021 | 72.8% | CN¥948.48 Million | CN¥1.30 Billion | CN¥353.53 Million | ▼ -2.1 pp |
| 2020 | 74.9% | CN¥678.97 Million | CN¥906.52 Million | CN¥227.55 Million | ▼ -0.3 pp |
| 2019 | 75.2% | CN¥653.98 Million | CN¥869.18 Million | CN¥215.19 Million | ▲ +2.1 pp |
| 2018 | 73.1% | CN¥580.93 Million | CN¥794.19 Million | CN¥213.26 Million | ▼ -8.7 pp |
| 2017 | 81.9% | CN¥517.68 Million | CN¥632.30 Million | CN¥114.61 Million | ▲ +7.4 pp |
| 2016 | 74.5% | CN¥276.11 Million | CN¥370.78 Million | CN¥94.66 Million | ▲ +1.6 pp |
| 2015 | 72.9% | CN¥235.08 Million | CN¥322.63 Million | CN¥87.55 Million | ▲ +4.7 pp |
| 2014 | 68.1% | CN¥200.15 Million | CN¥293.78 Million | CN¥93.63 Million | ▼ -0.6 pp |
| 2013 | 68.7% | CN¥165.93 Million | CN¥241.42 Million | CN¥75.49 Million | ▼ -0.8 pp |
| 2012 | 69.6% | CN¥132.65 Million | CN¥190.67 Million | CN¥58.03 Million | — |